Investigating the biology and treatment targets of infantile rhabdomyosarcoma
Official title: Understanding Infantile Rhabdomyosarcoma Biology and Therapeutic Targets
Funded at Research Inst Nationwide Children's Hosp · NIH-11065573 · Data updated 2026-11-12
This study is looking into a type of cancer called infantile rhabdomyosarcoma that affects young kids, and it's trying to find out how certain genes, especially one called VGLL2-NCOA2, might help us discover better treatments beyond just chemotherapy and surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | September 23, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $68,183 |
| NIH project number | 3R01CA272872-03S1 |
| Project ID | NIH-11065573 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old diagnosed with infantile rhabdomyosarcoma.
✕Less likely to help
Patients with other types of cancers or those older than 11 years may not benefit from this research.
What this research studies
This research focuses on understanding infantile rhabdomyosarcoma (RMS), an aggressive cancer affecting young children. The study aims to explore the genetic factors that contribute to this cancer, particularly a specific gene fusion known as VGLL2-NCOA2, which plays a role in muscle development. By utilizing various models, including zebrafish and mice, along with patient samples, the research seeks to identify new therapeutic targets that could lead to more effective treatments. The ultimate goal is to improve treatment options beyond the current reliance on general chemotherapy and surgery.
Why it matters
Potential benefit: If successful, this research could lead to more targeted and effective treatments for infantile rhabdomyosarcoma, reducing the need for harsh chemotherapy and improving outcomes for young patients.
How similar studies have gone: While there has been limited research specifically targeting infantile rhabdomyosarcoma, similar approaches in understanding cancer biology and targeting genetic factors have shown promise in other cancer types.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Kendall, Genevieve Claire — Research Inst Nationwide Children's Hosp
- Study coordinator: Kendall, Genevieve Claire
Related research
Other NIH-funded projects on the same topics.
-
Targeting the PAX3-FOXO1 protein in a deadly childhood cancer
This study is looking at a specific protein that helps a tough childhood cancer called alveolar rhabdomyosarcoma, with the goal of finding new ways to treat kids who have this illness.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
-
Genetically engineered mouse model to study and treat high-risk pediatric rhabdomyosarcoma
A research project aims to create mouse models that mimic high-risk pediatric rhabdomyosarcoma and test therapies that target the NOTCH1 pathway to slow or stop tumor growth.
-
Understanding infantile rhabdomyosarcoma biology and new treatment targets
A new grant is studying why infantile rhabdomyosarcoma develops and what drugs or strategies could specifically target it in young children.
-
Targeting CLK2 to Fight Rhabdomyosarcoma
Aims to see if blocking CLK2 can weaken rhabdomyosarcoma cancer cells, potentially offering a new treatment for kids and young adults.
-
Epitranscriptomic Crosstalk in Alveolar Rhabdomyosarcoma
A pediatric cancer study that looks at how chemical marks on messenger RNA may influence the behavior of alveolar rhabdomyosarcoma and point toward newer treatment strategies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.